Опыт применения капецитабина у больных раком молочной железы с метастазами в головной мозг

1. Chang E, Lob S. Diagnosis and Management of Central Nervous System Metastases from Breast Cancer. The Oncologist 2003; 8 (5): 398–410.
2. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–7.
3. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16: 1772–7.
4. De la Monte SM, Hutchins GM, Moore GW. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984; 76: 11–7.
5. Heinrich B, Brudler O, Siekiera W et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003 22: 37 (abstr 147).
6. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608–17.
7. Samaan NA, Buzdar AU, Aldinger KA et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981; 47: 554–60.
8. Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487–96.
9. Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295–304.
10. Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006; 3: CD003869.
11. Rosner D, Flower A, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993; 12: 508a.
12. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–9.
13. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8: 327–34.
14. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599–605.
15. Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 2001; 24: 256–60.
16. Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005; 71: 61–5.
17. Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006; 24: 466–8.
18. Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006; 15: 97–9.
19. Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003; 5: 833–4.
20. Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001; 24: 421–4.

Д.Р.Насхлеташвили, Г.Е.Чмутин, В.Б.Карахан, В.А.Алешин, Р.Г.Фу, Д.М.Белов, Е.А.Иванова

ГУ РОНЦ им. Н.Н.Блохина РАМН., Москва